N-of-1 for Beta-Blockers in Cardiac Amyloidosis

PHASE4Enrolling by invitationINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 31, 2024

Primary Completion Date

March 30, 2026

Study Completion Date

December 31, 2026

Conditions
Cardiac AmyloidosisHeart DiseasesTTR Cardiac Amyloidosis
Interventions
DRUG

Beta blocker

"The intervention is a single-arm crossover withdrawal/reversal design (On vs Off) with 2 total periods, each period lasting between up to 6 weeks. During the On period, subjects will be on their beta blocker. During the Off period, their beta blockers will be down-titrated by 50% each week and until subsequently discontinued (or the lowest dose the subject can safely tolerate).~Other Names:~* acebutolol~* atenolol~* betaxolol~* bisoprolol~* carvedilol~* labetalol~* metoprolol succinate~* metoprolol tartrate~* nadolol~* nebivolol~* penbutolol~* pindolol~* propranolol"

Trial Locations (1)

10065

Weill Cornell Medicine, New York

All Listed Sponsors
collaborator

U.S. Deprescribing Research Network

UNKNOWN

lead

Weill Medical College of Cornell University

OTHER